Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
3 studies found for:    22067384 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath  )
2 Active, not recruiting Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Conditions: Immunosuppresion;   Thrombocytopenia;   Pancytopenia;   Neutropenia
Interventions: Biological: Anti-thymocyte globulin (rabbit);   Biological: Anti-thymocyte globulin (horse);   Drug: Cyclosporine
3 Active, not recruiting Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Condition: Aplastic Anemia
Interventions: Drug: Alemtuzumab (Campath-1H);   Drug: Thymoglobulin (r-ATG);   Drug: Cyclosporine (CsA)
To Top

† Indicates status has not been verified in more than two years